| Literature DB >> 24904963 |
Celeste De Monte1, Simone Carradori2, Paola Chimenti1, Daniela Secci1, Luisa Mannina3, Francesca Alcaro4, Anél Petzer5, Clarina I N'Da5, Maria Concetta Gidaro4, Giosuè Costa4, Stefano Alcaro4, Jacobus P Petzer6.
Abstract
Although there are clinical trials and in vivo studies in literature regarding the anxiolytic and antidepressant activities of the components of Crocus sativus L., their effects on the human monoamine oxidases (hMAO-A and hMAO-B), enzymes which are involved in mental disorders and neurodegenerative diseases, have not yet been investigated. We have thus examined the hMAO inhibitory activities of crocin and safranal (the most important active principles in saffron) and, subsequently, designed a series of safranal derivatives to evaluate which chemical modifications confer enhanced inhibition of the hMAO isoforms. Docking simulations were performed in order to identify key molecular recognitions of these inhibitors with both isoforms of hMAO. In this regard, different mechanisms of action were revealed. This study concludes that safranal and crocin represent useful leads for the discovery of novel hMAO inhibitors for the clinical management of psychiatric and neurodegenerative disorders.Entities:
Keywords: Crocin; Crocus sativus L.; Depression; Neurodegenerative disorders; Safranal; hMAO inhibitors
Mesh:
Substances:
Year: 2014 PMID: 24904963 DOI: 10.1016/j.ejmech.2014.05.048
Source DB: PubMed Journal: Eur J Med Chem ISSN: 0223-5234 Impact factor: 6.514